Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | L3MBTL3 | Q96JM7 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.38 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | PHGDH | O43175 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4166916 | 0.98 | HTR6 (0.41) | HTR6L3MBTL3L3MBTL1MBTD1MEN1 | |
| SCHEMBL1831788 | 0.93 | — | — | |
| SCHEMBL192997 | 0.93 | — | — | |
| SCHEMBL477046 | 0.93 | — | — | |
| SCHEMBL3933942 | 0.88 | L3MBTL1 (0.39) | HTR6L3MBTL3L3MBTL1MBTD1LMNA | |
| SCHEMBL2008594 | 0.86 | L3MBTL3 (0.38) | HTR6L3MBTL3L3MBTL1MBTD1CYP2D6 | |
| SCHEMBL667548 | 0.86 | L3MBTL1 (0.40) | HTR6L3MBTL3L3MBTL1MBTD1LMNA | |
| SCHEMBL667276 | 0.86 | L3MBTL1 (0.40) | HTR6L3MBTL3L3MBTL1MBTD1LMNA | |
| SCHEMBL477164 | 0.86 | L3MBTL1 (0.40) | HTR6L3MBTL3L3MBTL1MBTD1LMNA | |
| SCHEMBL1833709 | 0.84 | L3MBTL3 (0.34) | HTR6L3MBTL3L3MBTL1MBTD1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 546 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3442977-B1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORP (US) | 2023-06-28 | — | — | EP | claimed |
| US-RE47689-E1 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2019-11-05 | — | — | US | claimed |
| EP-2809322-B9 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS INC (US) | 2019-10-30 | — | — | EP | claimed |
| EP-2809322-B1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS INC (US) | 2019-05-15 | — | — | EP | claimed |
| EP-3442977-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | Blueprint Medicines Corporation (US) | 2019-02-20 | — | — | EP | claimed |
| WO-2017181117-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION (US) | 2017-10-19 | — | — | WO | claimed |
| US-9617268-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2017-04-11 | — | — | US | claimed |
| US-20140296212-A1 | SUBSTITUTED PHENOXYPROPYLCYCLOAMINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | CEPHALON, INC. (US) | 2014-10-02 | — | — | US | claimed |
| EP-2784078-A1 | Benzoxepin pi3k inhibitor compounds and methods of use | F. Hoffmann-La Roche AG (CH) | 2014-10-01 | — | — | EP | claimed |
| US-8648067-B2 | Substituted phenoxypropylcycloamine derivatives as histamine-3 (H3) receptor ligands | CEPHALON, INC. (US) | 2014-02-11 | — | — | US | claimed |
| WO-2011036284-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | WO | claimed |
| US-20110076292-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | claimed |
| US-20110076291-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | claimed |
| US-20110059955-A1 | NOVEL 3-AMINOALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-03-10 | — | — | US | claimed |
| WO-2011002984-A1 | SUBSTITUTED PHENOXYPROPYLCYCLOAMINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | CEPHALON, INC. (US) | 2011-01-06 | — | — | WO | claimed |
| EP-2125741-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | Janssen Pharmaceutica, N.V. (BE) | 2009-12-02 | — | — | EP | claimed |
| US-20090099158-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-16 | — | — | US | claimed |
| WO-2008109336-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-12 | — | — | WO | claimed |
| US-20060183746-A1 | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds | CGI PHARMACEUTICALS, INC. | 2006-08-17 | — | — | US | claimed |
| EP-0251591-A1 | Oral hygiene composition | BEECHAM GROUP PLC (GB) | 1988-01-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099158-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH1 | HTR6 39/4885L3MBTL3 2511/4885L3MBTL1 2302/4885 |
| US-20140296212-A1 | SUBSTITUTED PHENOXYPROPYLCYCLOAMINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | HRH3, HRH4, HRH2 | HTR6 54/4885L3MBTL3 4624/4885L3MBTL1 4844/4885 |
| US-20110076291-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, NR2E1, NR2E3 | HTR6 3441/4885L3MBTL3 3746/4885L3MBTL1 3881/4885 |
| US-20110076292-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, PIK3CA, PI4KA | HTR6 3030/4885L3MBTL3 4046/4885L3MBTL1 4193/4885 |
| US-20110059955-A1 | NOVEL 3-AMINOALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | AVPR1B, AVPR1A, AVPR2 | HTR6 146/4885L3MBTL3 4742/4885L3MBTL1 4721/4885 |
| US-20060183746-A1 | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds | BTK, SYK, LCK | HTR6 3711/4885L3MBTL3 1030/4885L3MBTL1 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.